Birdie Biotech

Birdie Biotech is a private biotechnology company focused on targeted cancer immunotherapies and related therapeutic technologies. Publicly available company descriptions characterize the business as developing novel drug-conjugation approaches for cancer and autoimmune disease. Recent AACR 2026 abstract disclosures link the company name Birdiebio to BDB025, a preclinical small-molecule program designed to induce a synthetic mismatch-repair-deficient state and overcome resistance to PD-1 blockade in colorectal cancer. The company appears to be based in China, with Beijing cited by Crunchbase and Shanghai appearing in patent-oriented databases. Overall, Birdie Biotech appears to be an early-stage oncology platform company with limited public disclosure beyond directory listings and conference materials.